Inhalerx (ASX:IRX) — Material Events
ASX:IRX · 15 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
InhaleRx Secures $12.6M to Advance Oral Esketamine Therapy for DepressionMedium
InhaleRx secures $12.6M funding boost for SRX-25 development, total facility now $52.3M
4 Dec 2025
·Capital Raising
·85
InhaleRx Unveils Oral Esketamine SRX-25 to Transform Depression TreatmentMedium
InhaleRx launches oral Esketamine drug SRX-25 for Treatment-Resistant Depression, raises $1M capital
26 Nov 2025
·Capital Raising and Clinical Development Update
·85
InhaleRx Unveils Oral Esketamine Therapy and Rebrands to Nexalis TherapeuticsMedium
InhaleRx advances three fully funded drug candidates targeting pain and mental health with new oral TRD therapy and rebranding plans
10 Dec 2025
·Company Presentation
·85
InhaleRx Advances Clinical Trials, Raises $857k, and Plans Strategic RebrandMedium
InhaleRx advances clinical trials, raises $857k, extends $12.6m funding for new oral depression drug, plans rebrand
29 Jan 2026
·Quarterly Activities and Cashflow Report
·80
InhaleRx Advances Inhaled Cancer Pain and Panic Disorder Drugs with FDA BackingMedium
InhaleRx advances clinical trials for inhaled cancer pain and panic disorder drugs, FDA alignment achieved
31 Oct 2025
·Quarterly Activities and Cashflow Report
·75
InhaleRx Launches Phase 1 Trial of Rapid-Acting CBD Inhaler for Panic DisorderMedium
InhaleRx secures HREC approval for Phase 1 trial of inhaled CBD therapy IRX-616a for panic disorder
28 Aug 2025
·Clinical Trial Announcement
·75
InhaleRx Advances Clinical Trials with $38.5M Funding Boost and Ethics ApprovalMedium
InhaleRx advances IRX-211 and IRX-616a clinical trials with funding drawdown and ethics approvals
22 July 2025
·Quarterly Activities and Cashflow Report
·70
InhaleRX Launches $247K Entitlement Offer with Free Attaching OptionsMedium
InhaleRX launches $247K entitlement offer with free attaching options to existing shareholders
26 Nov 2025
·Entitlement Offer Prospectus
·70
InhaleRx Secures $857K in Capital Raise to Advance Inhaled TherapiesMedium
InhaleRx closes entitlement offer and placement raising $857,730 to fund clinical-stage drug development
23 Dec 2025
·Capital Raising
·70
Inhalerx Secures $51M in Funding Amid $628K Quarterly Cash BurnMedium
Inhalerx reports $628K operating cash burn, secures $38.5M and $12.6M clinical trial funding facilities
29 Jan 2026
·Quarterly Cash Flow Report
·70
InhaleRx Finalises $600K Share Placement to Boost Clinical PipelineMedium
InhaleRx completes $600K share placement tranche to fund clinical drug development
9 Jan 2026
·Capital Raising
·70
InhaleRx Advances Clinical Trials Amid Rising Losses and $38.5M Funding BoostMedium
InhaleRx reports increased half-year loss, advances clinical trials with $38.5M funding facility
25 Aug 2025
·Appendix 4D Half-year report
·70
InhaleRx Advances $1M Capital Raise to Fuel Clinical Drug PipelineMedium
InhaleRx raises $427,500 in initial placement tranche to fund clinical-stage drug development
9 Dec 2025
·Capital Raising
·70
Inhalerx Draws $247K to Fuel Phase 2 Trials, Cash Burn Hits $310K This QuarterMedium
Inhalerx draws $247K from $38.5M facility to fund clinical trials, reports $310K operating cash burn
31 Oct 2025
·Quarterly Cash Flow Report
·60
Inhalerx Taps $247K from $38.5M Facility to Fuel Phase 2 TrialsMedium
Inhalerx draws $247K from $38.5M biotech funding facility to support clinical trials, reports positive operating cash flow
22 July 2025
·Quarterly Cash Flow Report
·60
No articles in this tier for the last 12 months.
Market Mentions
1
- appeared in market wrap coverage
These are market wrap articles where Inhalerx (ASX:IRX) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026